About Julia Hemmendinger, ARK Analyst
Julia left ARK in 2018.
She joined ARK as a thematic analyst on the Genomic Revolution team in July of 2016. Her focus is on bioinformatics, instrumentation, molecular diagnostics and agricultural biology. Prior to ARK, Julia was an Analyst in the Private Fund Group at Credit Suisse in New York. She is a graduate of Stanford University with a Bachelor of Arts degree in Political Science.
Research by Julia Hemmendinger, ARK Analyst
July 01, 2017 | by Julia Hemmendinger, ARK Analyst | Health
A molecular diagnostic test for colorectal cancer could lower the age at which testing makes economic sense, an important consideration for a disease increasingly prevalent in younger people. As ARK has documented previously, early diagnosis could have a more profound impact on cancer care than could any of the promising next-generation treatments in the pipeline. […]February 16, 2017 | by Julia Hemmendinger, ARK Analyst | Health
Next generation genetic tests aim to provide cancer diagnostics at a very early stage, potentially saving millions of lives per year and generating hundreds of billions in revenue. Given the pace of improvement in their specificity and reliability, molecular diagnostic tests could make more progress against cancer in the next decade than have all the […]